Belfast-based technology and services provider Diaceutics has reported a return to profitability alongside strong revenue growth for the year ending 31 December 2025, with revenues rising 20% to £38.4 million and a record order book of £38.9 million representing 56% growth on 2024, according to Insider Media.

The company reported a profit before tax of £300,000, recovering from a £1.9 million loss in the prior year, while adjusted EBITDA grew 80% to £7.6 million. Annual recurring revenue reached £20 million at the year-end, reflecting 19% growth.

Ryan Keeling, chief executive of Diaceutics, said: "2025 marked a significant milestone for Diaceutics. Against a backdrop of heightened budget discipline across pharma and biotech, we delivered strong revenue growth, returned the business to profitability, and continued to scale our platform globally."

Keeling added that momentum improved through the fourth quarter, resulting in a strong finish to the year, with Q1 2026 trading performing in line with the board's expectations.

Diaceutics provides diagnostic intelligence services to pharmaceutical and biotech companies, helping clients identify patients, improve therapy adoption, and deliver measurable commercial impact. The company's platform model has demonstrated resilience amid a period of tightened budget discipline across the pharmaceutical and biotechnology sectors globally.

The record order book of £38.9 million at year-end underscores the growing demand for diagnostic intelligence solutions as pharmaceutical companies increasingly rely on precision data tools to support commercial launches and therapy access programmes across complex healthcare markets.

Read the full article for further detail on Diaceutics' 2025 financial results and platform performance.